Skip to main content

Table 2 Subgroup analysis of the grade 3 or higher adverse events

From: The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis

Experimental vs. control No. of studies RR 95% CI p Heterogeneity
(I2) (%)
Grade 3 or higher adverse events 8 1.87 1.27–2.77 0.002 96
Grade 3 or higher abdominal pain 9 1.08 0.69–1.68 0.74 0
Grade 3 or higher anemia 10 9.94 2.63–37.50 < 0.001 92
Grade 3 or higher arthralgia 7 0.81 0.32–2.03 0.66 0
Grade 3 or higher constipation 9 0.92 0.31–2.72 0.88 16
Grade 3 or higher decreased appetite 6 2.39 0.76–7.52 0.14 0
Grade 3 or higher diarrhea 8 0.92 0.53–1.59 0.75 0
Grade 3 or higher dizziness 6 0.85 0.12–5.99 0.87 36
Grade 3 or higher fatigue 10 2.39 1.67–3.44 < 0.001 0
Grade 3 or higher headache 8 0.55 0.22–1.37 0.20 0
Grade 3 or higher nausea 9 2.57 1.57–4.22 < 0.001 0
Grade 3 or higher neutropenia 9 2.42 1.41–4.17 0.001 81
Grade 3 or higher thrombocytopenia 8 4.66 1.26–17.19 0.02 84
Grade 3 or higher vomiting 9 1.43 0.86–2.37 0.17 0